Actively Recruiting
Randomized Study Assessing Safety of Anumigilimab Compared to Placebo in Adults with Sickle Cell Disease
Led by CSL Behring · Updated on 2026-11-03
63
Participants Needed
38
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of anumigilimab, a biological drug, in adults with sickle cell disease SCD. This phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study aims to determine the maximum tolerated dose of anumigilimab when given subcutaneously and to monitor its safety over a long treatment period. The study involves participants with confirmed SCD who have experienced vaso-occlusive crises requiring medical treatment within the past year. Participants will be randomly assigned to receive either anumigilimab or a matching placebo. The treatment includes a 12-week dose escalation period where the dose is increased to each participants individual maximum tolerated dose based on safety and neutrophil counts, followed by a 52-week maintenance period at that dose. The placebo group will receive volume-matched saline injections subcutaneously. The study uses a quadruple-blind design to ensure unbiased evaluation. During the 64 weeks of treatment, participants will be closely monitored for adverse events, changes in laboratory assessments, vital signs, and immune responses. The primary outcomes focus on treatment-emergent adverse events, adverse events of special interest, and clinically relevant changes from baseline. Secondary outcomes include serum concentration of the drug and the annualized rate of vaso-occlusive crises during maintenance. The study lasts until 75 weeks from baseline, assessing safety and tolerability throughout.
CONDITIONS
Brief Title
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Research Team
T
Trial Registration Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here